Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 519

1.

Increased oxygenation in the non-contracting forearm muscle during contralateral skillful hand movement.

Asahara R, Ishii K, Okamoto I, Sunami Y, Hamada H, Kataoka T, Ohshita W, Watanabe T, Matsukawa K.

Exp Physiol. 2020 Mar 18. doi: 10.1113/EP088194. [Epub ahead of print]

PMID:
32187775
2.

Neck dissection prolongs survival in patient with stage IVC hypopharyngeal carcinoma with mixed responses to nivolumab.

Ito T, Sato H, Tsujikawa T, Hirai H, Okamoto I, Miyake K, Nagao T, Tsukahara K.

Auris Nasus Larynx. 2020 Mar 12. pii: S0385-8146(20)30064-X. doi: 10.1016/j.anl.2020.02.014. [Epub ahead of print]

PMID:
32173169
3.

Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.

Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, Azuma K, Yoneshima Y, Murakami H, Hosomi Y, Atagi S, Ozaki T, Horiike A, Fujita Y, Okamoto H, Ando M, Yamamoto N, Ohe Y, Nakagawa K.

JAMA Oncol. 2020 Mar 12:e196828. doi: 10.1001/jamaoncol.2019.6828. [Epub ahead of print]

PMID:
32163097
4.

A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients.

Sekine I, Shintani Y, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Dosaka-Akita H, Takiguchi Y, Miyaoka E, Okumura M, Yoshino I.

Cancer Sci. 2020 Feb 26. doi: 10.1111/cas.14368. [Epub ahead of print]

5.

The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma.

Hirai H, Tada Y, Nakaguro M, Kawakita D, Sato Y, Shimura T, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Fushimi C, Shimizu A, Okamoto I, Takase S, Okada T, Sato H, Imanishi Y, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Saigusa N, Takahashi H, Ando M, Urano M, Hanazawa T, Nagao T.

Virchows Arch. 2020 Feb 26. doi: 10.1007/s00428-020-02777-w. [Epub ahead of print]

PMID:
32103349
6.

Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.

Inoue H, Okamoto I.

Lung Cancer (Auckl). 2019 Dec 31;10:161-170. doi: 10.2147/LCTT.S184380. eCollection 2019. Review.

7.

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.

Tokudome N, Koh Y, Akamatsu H, Fujimoto D, Okamoto I, Nakagawa K, Hida T, Imamura F, Morita S, Yamamoto N.

BMC Cancer. 2020 Feb 6;20(1):103. doi: 10.1186/s12885-020-6593-1.

8.

Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.

Takada K, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Takamori S, Toyokawa G, Oba T, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M.

J Cancer Res Clin Oncol. 2020 Feb 5. doi: 10.1007/s00432-020-03146-5. [Epub ahead of print]

PMID:
32025867
9.

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.

Takahama T, Azuma K, Shimokawa M, Takeda M, Ishii H, Kato T, Saito H, Daga H, Tsuboguchi Y, Okamoto I, Otsubo K, Akamatsu H, Teraoka S, Takahashi T, Ono A, Ohira T, Yokoyama T, Sakai K, Yamamoto N, Nishio K, Nakagawa K.

Cancer. 2020 Feb 5. doi: 10.1002/cncr.32749. [Epub ahead of print]

PMID:
32022929
10.

Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.

Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC.

Clin Lung Cancer. 2020 Mar;21(2):e84-e88. doi: 10.1016/j.cllc.2019.12.006. Epub 2019 Dec 28.

PMID:
31948903
11.

Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3.

Yoshioka H, Kato T, Okamoto I, Tanaka H, Hida T, Seto T, Kiura K, Tian Y, Azuma H, Yamamoto N.

Future Oncol. 2020 Feb;16(4):49-60. doi: 10.2217/fon-2019-0659. Epub 2020 Jan 10.

12.

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).

Seto T, Azuma K, Yamanaka T, Sugawara S, Yoshioka H, Wakuda K, Atagi S, Iwamoto Y, Hayashi H, Okamoto I, Saka H, Mitsuoka S, Fujimoto D, Nishino K, Horiike A, Daga H, Sone T, Yamamoto N, Nakagawa K, Nakanishi Y.

J Clin Oncol. 2020 Mar 10;38(8):793-803. doi: 10.1200/JCO.19.01494. Epub 2019 Dec 27.

PMID:
31880966
13.

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

Yonesaka K, Iwama E, Hayashi H, Suzuki S, Kato R, Watanabe S, Takahama T, Tanizaki J, Tanaka K, Takeda M, Sakai K, Azuma K, Chiba Y, Atagi S, Nishio K, Okamoto I, Nakagawa K.

Sci Rep. 2019 Dec 20;9(1):19501. doi: 10.1038/s41598-019-55939-5.

14.

Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.

Morita R, Okishio K, Shimizu J, Saito H, Sakai H, Kim YH, Hataji O, Yomota M, Nishio M, Aoe K, Kanai O, Kumagai T, Kibata K, Tsukamoto H, Oizumi S, Fujimoto D, Tanaka H, Mizuno K, Masuda T, Kozuki T, Haku T, Suzuki H, Okamoto I, Hoshiyama H, Ueda J, Ohe Y.

Lung Cancer. 2020 Feb;140:8-18. doi: 10.1016/j.lungcan.2019.11.014. Epub 2019 Nov 20.

15.

Post-operative complications due to salvage total laryngectomy for recurrent laryngeal cancer after radiotherapy - a multicentre retrospective study.

Okamoto I, Matsuki T, Sato H, Kondo T, Fushimi C, Okada T, Miura K, Yamashita T, Omura G, Tsukahara K.

Acta Otolaryngol. 2020 Feb;140(2):170-174. doi: 10.1080/00016489.2019.1699251. Epub 2019 Dec 11.

PMID:
31825701
16.

Induction of the germ cell fate from pluripotent stem cells in cynomolgus monkeys†.

Sakai Y, Nakamura T, Okamoto I, Gyobu-Motani S, Ohta H, Yabuta Y, Tsukiyama T, Iwatani C, Tsuchiya H, Ema M, Morizane A, Takahashi J, Yamamoto T, Saitou M.

Biol Reprod. 2020 Mar 13;102(3):620-638. doi: 10.1093/biolre/ioz205.

PMID:
31724030
17.

Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.

Iwama E, Goto Y, Murakami H, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Nishitsuji M, Akamatsu H, Morinaga R, Akagi T, Shimose T, Tokunaga S, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I.

Oncologist. 2019 Oct 30. pii: theoncologist.2019-0728. doi: 10.1634/theoncologist.2019-0728. [Epub ahead of print]

18.

Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.

Tsuchiya-Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I.

Oncologist. 2019 Oct 24. pii: theoncologist.2019-0746. doi: 10.1634/theoncologist.2019-0746. [Epub ahead of print]

19.

Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation.

Tsutsumi H, Yoneshima Y, Ota K, Otsubo K, Iwama E, Inoue H, Tanaka K, Nakanishi Y, Okamoto I.

Clin Lung Cancer. 2020 Jan;21(1):e21-e24. doi: 10.1016/j.cllc.2019.09.001. Epub 2019 Sep 26. No abstract available.

PMID:
31649000
20.

Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy.

Ikematsu Y, Tanaka K, Yanagihara T, Liu R, Inoue H, Yoneshima Y, Ota K, Iwama E, Takata S, Hata K, Takahata Y, Wataya H, Nakanishi Y, Okamoto I.

Lung Cancer. 2019 Dec;138:58-64. doi: 10.1016/j.lungcan.2019.10.011. Epub 2019 Oct 13.

PMID:
31639551
21.

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.

Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T.

Ann Oncol. 2019 Dec 1;30(12):1978-1984. doi: 10.1093/annonc/mdz399.

PMID:
31553438
22.

18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer.

Takada K, Toyokawa G, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Haro A, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M.

Sci Rep. 2019 Sep 16;9(1):13362. doi: 10.1038/s41598-019-50079-2.

23.

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.

Iwama E, Sakai K, Hidaka N, Inoue K, Fujii A, Nakagaki N, Ota K, Toyozawa R, Azuma K, Nakatomi K, Harada T, Hisasue J, Sakata S, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Cancer. 2020 Jan 1;126(1):219-227. doi: 10.1002/cncr.32481. Epub 2019 Sep 10.

PMID:
31503343
24.

Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).

Nishio M, Sugawara S, Atagi S, Akamatsu H, Sakai H, Okamoto I, Takayama K, Hayashi H, Nakagawa Y, Kawakami T.

Clin Lung Cancer. 2019 Nov;20(6):469-476.e1. doi: 10.1016/j.cllc.2019.07.005. Epub 2019 Jul 31.

PMID:
31466854
25.

Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study.

Okamoto I, Sato H, Kondo T, Koyama N, Fushimi C, Okada T, Miura K, Matsuki T, Yamashita T, Omura G, Tsukahara K.

Acta Otolaryngol. 2019 Oct;139(10):918-925. doi: 10.1080/00016489.2019.1648867. Epub 2019 Aug 28.

PMID:
31460818
26.

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.

Udagawa H, Akamatsu H, Tanaka K, Takeda M, Kanda S, Kirita K, Teraoka S, Nakagawa K, Fujiwara Y, Yasuda I, Okubo S, Shintani M, Kosloski MP, Scripture C, Tamura T, Okamoto I.

Lung Cancer. 2019 Sep;135:145-150. doi: 10.1016/j.lungcan.2019.07.025. Epub 2019 Jul 24.

PMID:
31446987
27.

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden S, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam SS.

Clin Cancer Res. 2019 Nov 15;25(22):6644-6652. doi: 10.1158/1078-0432.CCR-19-1126. Epub 2019 Aug 22.

PMID:
31439584
28.

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.

Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K; DLD/TO Assemblies of JRS.

Respir Investig. 2019 Nov;57(6):512-533. doi: 10.1016/j.resinv.2019.06.001. Epub 2019 Aug 1. Review.

PMID:
31377122
29.

Pituitary-adrenal dysfunction caused by nivolumab for head and neck cancer.

Hihara K, Sato H, Okamoto I, Katsube Y, Maruyama R, Tomioka R, Tanaka H, Tsukahara K.

Auris Nasus Larynx. 2019 Dec;46(6):896-901. doi: 10.1016/j.anl.2019.02.005. Epub 2019 Jul 23.

PMID:
31350019
30.

Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.

Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, Uchida H, Vowler SL, Mitsudomi T.

Cancer Sci. 2019 Sep;110(9):2884-2893. doi: 10.1111/cas.14120. Epub 2019 Aug 1.

31.

Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.

Takada K, Shimokawa M, Tanaka K, Kohashi K, Haro A, Osoegawa A, Tagawa T, Azuma K, Okamoto I, Oda Y, Mori M.

PLoS One. 2019 Jun 4;14(6):e0217991. doi: 10.1371/journal.pone.0217991. eCollection 2019.

32.

Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).

Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Maruyama R, Nakagaki N, Shimada M, Ikeda T, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Okamoto I, Ichinose Y, Sugio K.

Lung Cancer. 2019 Jun;132:1-8. doi: 10.1016/j.lungcan.2019.01.008. Epub 2019 Apr 5.

PMID:
31097081
33.

N-Ethynylation of Anilides Decreases the Double-Bond Character of Amide Bond while Retaining trans-Conformation and Planarity.

Yamasaki R, Morita K, Iizumi H, Ito A, Fukuda K, Okamoto I.

Chemistry. 2019 Aug 1;25(43):10118-10122. doi: 10.1002/chem.201901451. Epub 2019 Jun 26.

PMID:
31050845
34.

Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study).

Akamatsu H, Koh Y, Okamoto I, Fujimoto D, Bessho A, Azuma K, Morita S, Yamamoto N, Nakagawa K.

Lung Cancer. 2019 May;131:128-133. doi: 10.1016/j.lungcan.2019.03.021. Epub 2019 Mar 22.

35.

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.

Otsubo K, Sakai K, Takeshita M, Harada D, Azuma K, Ota K, Akamatsu H, Goto K, Horiike A, Kurata T, Nakagaki N, Nosaki K, Iwama E, Nakanishi Y, Nishio K, Okamoto I.

Oncologist. 2019 Aug;24(8):1022-1026. doi: 10.1634/theoncologist.2019-0101. Epub 2019 Apr 25.

36.

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting.

Park K, Wan-Teck Lim D, Okamoto I, Yang JC.

Ther Adv Med Oncol. 2019 Apr 15;11:1758835919836374. doi: 10.1177/1758835919836374. eCollection 2019. Review.

37.

A symmetric toggle switch explains the onset of random X inactivation in different mammals.

Mutzel V, Okamoto I, Dunkel I, Saitou M, Giorgetti L, Heard E, Schulz EG.

Nat Struct Mol Biol. 2019 May;26(5):350-360. doi: 10.1038/s41594-019-0214-1. Epub 2019 Apr 8.

38.

Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.

Yoneshima Y, Tanaka K, Shiraishi Y, Hata K, Watanabe H, Harada T, Otsubo K, Iwama E, Inoue H, Masuda S, Nakanishi Y, Okamoto I.

Lung Cancer. 2019 Apr;130:5-9. doi: 10.1016/j.lungcan.2019.01.014. Epub 2019 Jan 29.

PMID:
30885351
39.

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.

Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T.

Int J Clin Oncol. 2019 May;24(5):485-493. doi: 10.1007/s10147-019-01396-z. Epub 2019 Mar 4.

40.

A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.

Matsubara T, Takada K, Azuma K, Takamori S, Toyokawa G, Haro A, Osoegawa A, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1925-1933. doi: 10.1245/s10434-019-07257-3. Epub 2019 Feb 27.

PMID:
30815803
41.

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.

Takamori S, Takada K, Azuma K, Jogo T, Shimokawa M, Toyokawa G, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1916-1924. doi: 10.1245/s10434-019-07231-z. Epub 2019 Feb 27.

PMID:
30815801
42.

Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.

Sato H, Tsukahara K, Okamoto I, Katsube Y, Shimizu A, Kondo T, Hanyu K, Fushimi C, Okada T, Miura K.

Acta Otolaryngol. 2019 Feb;139(2):201-205. doi: 10.1080/00016489.2018.1551623. Epub 2019 Feb 22.

PMID:
30794080
43.

Post-operative complications of salvage total laryngectomy forpost-radiotherapy recurrent laryngeal cancer using pectoralis major myocutaneous flaps.

Okamoto I, Tsukahara K, Shimizu A, Sato H.

Acta Otolaryngol. 2019 Feb;139(2):167-171. doi: 10.1080/00016489.2018.1532108. Epub 2019 Feb 22.

PMID:
30794035
44.

Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor.

Hino T, Kamitani T, Sagiyama K, Yamasaki Y, Okamoto I, Tagawa T, Ijichi K, Yamamoto H, Yabuuchi H, Honda H.

Eur J Radiol Open. 2019 Jan 31;6:72-77. doi: 10.1016/j.ejro.2019.01.006. eCollection 2019.

45.

Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer.

Kubo N, Harada T, Shiraishi Y, Nosaki K, Nakagaki N, Takeshita M, Ouchi H, Iwama E, Tanaka K, Okamoto I, Sasaki H, Nakanishi Y.

Anticancer Res. 2019 Feb;39(2):671-677. doi: 10.21873/anticanres.13162.

PMID:
30711944
46.

Classification of tumors by imaging diagnosis and preoperative fine-needle aspiration cytology in 120 patients with tumors in the parapharyngeal space.

Matsuki T, Miura K, Tada Y, Masubuchi T, Fushimi C, Kanno C, Takahashi H, Kamata S, Okamoto I, Miyamoto S, Yamashita T.

Head Neck. 2019 May;41(5):1277-1281. doi: 10.1002/hed.25552. Epub 2019 Jan 8.

PMID:
30620436
47.

Risk Factors of Subsequent Primary Melanomas in Austria.

Müller C, Wendt J, Rauscher S, Sunder-Plassmann R, Richtig E, Fae I, Fischer G, Okamoto I.

JAMA Dermatol. 2019 Feb 1;155(2):188-195. doi: 10.1001/jamadermatol.2018.4645.

48.

Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.

Anai S, Iwama E, Yoneshima Y, Otsubo K, Tanaka K, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Dec;126:156-161. doi: 10.1016/j.lungcan.2018.11.002. Epub 2018 Nov 5.

PMID:
30527181
49.

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.

Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K.

Jpn J Clin Oncol. 2019 Jan 1;49(1):29-36. doi: 10.1093/jjco/hyy179.

50.

Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.

Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Nov;125:136-141. doi: 10.1016/j.lungcan.2018.09.014. Epub 2018 Sep 18.

PMID:
30429011

Supplemental Content

Loading ...
Support Center